Novo Nordisk wants to make another major capital investment in production capacity for its diabetes and obesity therapies. The Danish drugmaker announced to spend more than 16 billion Danish kroner (€2.1 billion euros) starting in 2023 to expand its production site in Chartres, France, adding aseptic production and finished production processes and an extension of the current Quality Control Laboratory.
Last week, Lonza and Vertex Pharmaceuticals broke ground on a new US facility in Portsmouth, New Hampshire, to manufacture cell therapies for diabetes.
Danish drugmaker Novo Nordisk has agreed to acquire Montreal, Canada-based Inversago Pharma. The transaction is worth up to $1.075 billion in cash if certain development and commercial milestones are achieved, the companies said in a statement.
US-based Vertex Pharmaceuticals has agreed to pay $320 million in cash to acquire ViaCyte, a compatriot private cellular therapy company specializing in a treatment for type-1 diabetes (T1D). The transaction is expected to close later this year.
